4月28日，凯因科技(688687)披露2024年年度报告和2025年一季报。公司2024年度实现营业收入12.30亿 元，归母净利润1.42亿元，同比增长22.18%；2025年一季度实现营收2.32亿元，同比增长8.90%，归母 净利润2566.85万元，同比增长15.92%。公司维持较高研发投入强度，2024年研发投入1.57亿元，占营 业收入比例为12.79%，同比增加0.57个百分点。核心项目取得突破性进展 报告期内，公司多个研发项目取得突破性进展：KW-001(培集成干扰素α-2注射液乙肝适应症)完成Ⅲ期 临床试验并提交药品注册上市许可申请；KW-045(人干扰素α2b喷雾剂)针对儿童疱疹性咽峡炎适应症 Ⅱa期临床试验全部受试者完成治疗及随访；KW-051(培集成干扰素α-2注射液带状疱疹适应症)Ⅱ期临床 试验全部受试者完成治疗及随访；KW-053人干扰素α2b阴道泡腾片辅助治疗尖锐湿疣适应症取得药物临 床试验批准通知书，Ⅱ期试验推进中；GL-004(马来酸阿伐曲泊帕片)取得药品注册证书。 公司于2024年共申请发明专利9项，获得发明专利授权7项；至报告期末，累计申请发明专利175项，累 计获得发 ...

中国经济网北京4月22日讯凯因科技(688687.SH)昨晚发布关于股东减持股份计划的公告显示，公司于近 日收到北京富山湾投资管理中心(有限合伙)(简称"富山湾")、北京富宁湾投资管理中心(有限合伙)(简 称"富宁湾")、北京卓尚石投资管理中心(有限合伙)(简称"卓尚石")、北京卓尚湾企业管理中心(有限合 伙)(简称"卓尚湾")出具的《股份减持计划告知函》。 富山湾、富宁湾、卓尚石、卓尚湾因其持有人自身资金需求，拟通过集中竞价及大宗交易的方式减持其 所持有的公司股份合计不超过5,128,000股，即不超过公司总股本的3.00%。自减持计划公告之日起15个 交易日后的3个月内(2025年5月16日至2025年8月15日)实施。 上述股份的减持价格均根据市场价格确定，若在减持计划实施期间公司发生派息、送股、资本公积转增 股本、配股等除权除息事项，将根据股本变动对减持数量进行相应调整。 公司实际控制人周德胜承诺不通过本次减持计划减持其间接持有的公司股份。 2024年2月3日，凯因科技发布以简易程序向特定对象发行人民币普通股股票预案。凯因科技本次以简易 程序向特定对象发行人民币普通股股票总额不超过人民币30,000. ...

证券代码：688687 证券简称：凯因科技 公告编号：2025-002 北京凯因科技股份有限公司 关于股东减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 股东持有的基本情况 截至本公告披露日，北京凯因科技股份有限公司（以下简称"公司"）股东： 北京富山湾投资管理中心（有限合伙）（以下简称"富山湾"）直接持有公司股份 3,156,600 股，占公司总股本的 1.85%；北京富宁湾投资管理中心（有限合伙） （以下简称"富宁湾"）直接持有公司股份 3,113,100 股，占公司总股本的 1.82%； 北京卓尚石投资管理中心（有限合伙）（以下简称"卓尚石"）直接持有公司股份 1,673,300 股，占公司总股本的 0.98%；北京卓尚湾企业管理中心（有限合伙） （以下简称"卓尚湾"）直接持有公司股份 1,043,922 股，占公司总股本的 0.61%。 富山湾、富宁湾、卓尚石、卓尚湾均属于公司实际控制人能够控制的企业，上述 股东合计持有公司股份 8,986,922 股，占公司总股本的 ...

Revenue Performance - Total revenue for 2024 was RMB 123,106.46 million, a decrease of 12.81% compared to the previous year[5] - The decline in total revenue was influenced by the implementation of centralized procurement policies for core products, leading to price reductions[5] Profitability - Net profit attributable to shareholders was RMB 14,383.47 million, an increase of 23.44% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 13,844.86 million, up 12.95% from the previous year[5] - Basic earnings per share increased to RMB 0.86, representing a growth of 22.86% compared to the previous year[3] - The weighted average return on equity rose to 8.01%, an increase of 1.20 percentage points[3] Assets and Equity - Total assets at the end of the reporting period were RMB 261,646.97 million, reflecting a year-on-year growth of 6.87%[5] - Shareholders' equity attributable to the parent company was RMB 184,471.26 million, an increase of 5.18% year-on-year[5] Cost Management - The company continued to promote cost reduction and efficiency enhancement strategies, resulting in a decrease in overall sales input ratio[5] Financial Stability - No financial data or indicators showed a change of 30% or more during the reporting period[6]

上 海 证 券 交 易 所 上证科创公监函〔2024〕0059 号 关于对北京凯因科技股份有限公司及有关责任 人予以监管警示的决定 定期报告是投资者关注的重大事项，可能对公司股价及投资者 决策产生影响，公司理应根据会计准则对当期财务数据进行客观、 谨慎地核算并披露。公司多期定期报告财务信息披露不准确等行为， 违反了《上海证券交易所科创板股票上市规则》（以下简称《科创板 股票上市规则》）第 5.1.2 条、第 5.1.4 条等有关规定。 1 责任人方面，公司时任董事长兼总经理周德胜作为公司主要负 责人、信息披露第一责任人，时任财务负责人郭伟作为公司财务事 项的具体负责人，根据《行政监管措施决定书》的认定，对公司相 关违规行为负有主要责任，违反了《科创板股票上市规则》第 4.2.1 条、第 4.2.4 条、第 4.2.5 条、第 5.1.2 条等规定及其在《董事（监 事、高级管理人员）声明及承诺书》中做出的承诺。 鉴于上述违规事实和情节，根据《科创板股票上市规则》第 14.2.1 条、第 14.2.2 条和《上海证券交易所纪律处分和监管措施实 施办法》等有关规定，我部作出如下监管措施决定： 对北京凯因科技股份有限 ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2023, representing a 20% increase compared to the same period last year[2]. - The company has set a revenue guidance of 1.2 billion RMB for the full year 2023, indicating a projected growth of 25%[2]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the first half of 2023, representing a 25% year-over-year growth[19]. - The company provided a positive outlook for the second half of 2023, projecting a revenue growth of 30% year-over-year[19]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2023, representing a 20% year-over-year growth[161]. - The company reported a revenue increase of 15% year-over-year, reaching $500 million in the latest quarter[170]. - The company reported a significant increase in revenue, achieving a total of 550 million yuan in the first half of 2023, marking a year-on-year growth of 25%[176]. User Growth - User data showed a growth in active users to 1.2 million, up 15% year-over-year[2]. - User data indicates a growth in active users, reaching 500,000, which is a 40% increase compared to the previous year[19]. - User data showed a growth in active users, reaching 10 million, which is a 15% increase compared to the previous year[164]. - User data showed a growth of 20% in active users, totaling 2 million users by the end of the reporting period[171]. Product Development and R&D - New product launches contributed to 30% of total revenue, with significant demand in the biotechnology sector[2]. - The company is investing 100 million RMB in R&D for new technologies, focusing on innovative drug development[2]. - New product launches include the innovative antiviral drug, which is expected to generate an additional 200 million CNY in revenue by the end of the year[19]. - Research and development investments have increased by 20%, focusing on new drug formulations and delivery methods[19]. - The company’s R&D investment as a percentage of operating revenue was 10.49%, a decrease of 4.11 percentage points from 14.60% in the previous year[28]. - The company’s R&D investment totaled CNY 56.14 million, accounting for 10.49% of operating revenue, with 7 domestic invention patents applied and 3 granted during the reporting period[81]. - The company is investing $50 million in R&D for new technologies aimed at enhancing user experience[171]. Market Expansion - Market expansion efforts have led to a 10% increase in market share in the Asia-Pacific region[2]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2024[19]. - The company is currently developing a combination of functional cure drugs for hepatitis B and expanding its pipeline in the field of immune diseases[38]. - The company plans to enhance customer engagement through a new loyalty program, expected to increase customer retention by 20%[165]. - Market expansion plans include entering three new international markets by Q4 2023, aiming for a 10% market share in each[165]. Strategic Partnerships and Acquisitions - A strategic partnership was established with a leading pharmaceutical company to co-develop new therapies[2]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence[2]. - A new strategic partnership has been established with a leading biotechnology firm to co-develop next-generation therapies[19]. - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the tech sector[164]. Financial Position and Risks - The net profit attributable to shareholders decreased by 1.16% to ¥36,805,406.75 from ¥37,236,855.77 year-on-year[28]. - The net cash flow from operating activities fell significantly by 168.18%, resulting in a negative cash flow of ¥46,464,411.63, compared to a positive cash flow of ¥68,147,724.38 last year[28]. - The company has identified key risks, including regulatory changes and market competition, which are detailed in the risk factors section[2]. - The company faces risks related to new drug development, including potential clinical trial failures and regulatory changes, which could impact future revenue[89]. Environmental and Compliance - The company has established pollution prevention facilities with normal operation, including a wastewater treatment facility with a capacity of 300 tons per day[137]. - The company has maintained compliance with air and water pollution discharge standards throughout the reporting period[136]. - The company has developed an environmental self-monitoring plan and conducts monitoring through qualified third-party testing agencies, with real-time data being supervised by environmental authorities[141]. - The company has committed to avoiding and minimizing related party transactions, ensuring fair pricing in such transactions[148]. Shareholder Commitments - The controlling shareholder has pledged to hold shares for a minimum of 36 months post-IPO and will not transfer or manage shares during the lock-up period[150]. - Shareholder commitments include a promise not to sell shares for 36 months post-IPO, ensuring stability during the initial growth phase[162]. - The company commits to comply with regulations regarding shareholder reductions and will announce any reduction plans three trading days in advance[156].

根据《上市公司信息披露管理办法》（证监会令第182号）第五十一条、第五 十二条的规定，我局决定对你们采取责令改正的监管措施，并记入证券期货市场 诚信档案。你公司应该按照相关法律法规要求，提高财务核算规范化水平和信息 披露质量，依法履行信息披露义务，并于收到本决定书之日起15个工作日内向我 局报送书面整改报告。 如果对本监管措施不服，可以在收到本决定书之日起 60 日内向中国证券监 证券代码：688687 证券简称：凯因科技 公告编号：2024-055 北京凯因科技股份有限公司 关于收到《中国证券监督管理委员会北京监管局行政 监管措施决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京凯因科技股份有限公司于 2024 年 12 月 19 日收到中国证券监督管理委 员会北京监管局出具的《行政监管措施决定书》〔2024〕303 号，现将相关情况 公告如下： 一、《行政监管措施决定书》的主要内容 北京凯因科技股份有限公司、周德胜、郭伟： 经查，北京凯因科技股份有限公司（以下简称公司）存在以下问题：收入核 算管理不到 ...

2023 年第一季度报告 单位：元 币种：人民币 证券代码：688687 证券简称：凯因科技 北京凯因科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期 增减变动幅度 (%) | | 营业收入 | 159,332,225.42 | -7 ...

Financial Performance - The company's operating revenue for Q3 2023 reached ¥451,759,202.77, representing a year-on-year increase of 31.38%[6] - Net profit attributable to shareholders for Q3 2023 was ¥47,259,179.24, reflecting a significant increase of 51.68% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥48,384,333.38, up by 41.17% year-on-year[6] - Basic earnings per share for Q3 2023 were ¥0.28, up by 55.56% compared to the same period last year[10] - The net profit attributable to shareholders for the year-to-date period increased by 22.91% compared to the same period last year[12] - Net profit for the third quarter of 2023 was ¥94,938,760.33, up from ¥65,367,688.01 in the same quarter of 2022, reflecting a growth of approximately 45.4%[36] - The net profit attributable to shareholders of the parent company for the third quarter was ¥84,064,585.99, compared to ¥68,394,595.45 in the same quarter of 2022, reflecting an increase of approximately 22.9%[36] - The total comprehensive income attributable to the parent company reached ¥86,028,250.37, compared to ¥71,970,830.44 in the previous year, reflecting an increase of approximately 19.5%[39] - Basic and diluted earnings per share both increased to ¥0.50 from ¥0.40, marking a 25% growth year-over-year[39] Assets and Liabilities - The total assets as of the end of Q3 2023 amounted to ¥2,301,663,558.17, an increase of 4.16% from the end of the previous year[10] - The total assets as of the end of the reporting period were ¥2,301,663,558.17, compared to ¥2,209,724,972.77 at the end of the previous year, showing an increase of about 4.1%[30] - Total liabilities increased to ¥559,181,329.47 from ¥527,934,808.32, marking a rise of approximately 5.9%[30] - The equity attributable to shareholders of the parent company reached ¥1,721,057,722.32, up from ¥1,675,556,748.68, indicating an increase of about 2.7%[30] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥34,283,548.58, down by 65.38% compared to the previous year[10] - Cash inflow from operating activities totaled ¥976,228,103.10, up from ¥901,980,839.21, indicating a rise of about 8.2%[42] - The net cash flow from operating activities was ¥34,283,548.58, a decrease from ¥99,030,532.23, showing a decline of approximately 65.4%[42] - Cash inflow from investment activities amounted to ¥1,380,358,586.75, compared to ¥1,081,464,632.91, representing an increase of around 27.6%[42] - The net cash flow from investment activities was ¥126,864,704.63, a significant recovery from a negative cash flow of -¥615,586,129.26 in the previous year[42] - The company reported a net increase in cash and cash equivalents of ¥146,332,312.30, contrasting with a decrease of -¥572,651,999.32 in the prior year[42] - Total cash and cash equivalents at the end of the period stood at ¥866,918,251.56, up from ¥580,619,199.10, reflecting an increase of approximately 49.3%[42] Research and Development - The company's R&D investment totaled ¥30,415,977.66 in Q3 2023, accounting for 6.73% of operating revenue, a decrease of 2.34 percentage points year-on-year[10] - Research and development expenses for the third quarter of 2023 amounted to ¥68,195,871.59, slightly down from ¥69,860,306.50 in the previous year[33] Shareholder Information - The company reported a total of 7,787 common shareholders at the end of the reporting period[14] Strategic Focus and Future Outlook - The company has not disclosed any significant new product developments or technological advancements during this reporting period[20] - There are no indications of market expansion or mergers and acquisitions in the current report[20] - The company has not provided specific future guidance or performance outlook for the upcoming quarters[20] - The report does not mention any significant changes in shareholder structure or related party transactions[20] Operating Costs - Total operating revenue for the first three quarters of 2023 reached ¥986,914,134.12, an increase from ¥836,731,606.49 in the same period of 2022, representing a growth of approximately 17.9%[30] - Total operating costs for the first three quarters of 2023 were ¥873,480,654.54, compared to ¥779,995,200.30 in 2022, indicating an increase of about 12.0%[30] Other Financial Metrics - The weighted average return on equity for Q3 2023 was 2.72%, an increase of 0.88 percentage points year-on-year[10] - The company's long-term equity investments were reported at ¥4,314,100.90, a slight decrease from ¥4,371,655.95 at the end of 2022, showing a decline of approximately 1.3%[25] - The total current assets decreased slightly to ¥1,776,318,126.77 from ¥1,794,875,195.52, a decline of about 1.0%[25] - The company's accounts receivable increased to ¥395,853,210.34 from ¥333,297,094.96, reflecting a growth of about 18.7% year-over-year[25] - Inventory levels rose to ¥165,306,646.59, compared to ¥148,810,966.21 at the end of 2022, indicating an increase of approximately 11.0%[25] - The company's deferred income tax liabilities were reported at ¥6,658,707.03, an increase from ¥5,112,008.42 in the previous year[30] - The total assets held for sale were not reported, indicating a potential area for future strategic focus[25] - The company did not report any net profit from the merged entity prior to the merger, consistent with the previous year[39] - The company is not applying new accounting standards or interpretations that would affect the financial statements for the current year[44]

证券代码：688687 证券简称：凯因科技 公告编号：2024-059 北京凯因科技股份有限公司 关于北京证监局行政监管措施决定书的整改报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京凯因科技股份有限公司（以下简称"公司"）于 2024 年 12 月 19 日收 到中国证券监督管理委员会北京监管局（以下简称"北京证监局"）出具的《行 政监管措施决定书》（〔2024〕303 号）（以下简称《决定书》）。 收到上述《决定书》后，公司高度重视，召集相关部门和人员对《决定书》 所述事项进行分析讨论，积极落实整改。针对《决定书》中所涉及问题，严格按 照相关法律、法规和规范性文件以及《公司章程》的要求，结合公司现场检查情 况认真落实自查和梳理，深入分析问题原因，提出整改措施，并形成整改报告如 下： 一、存在的问题及整改措施 （一）问题一：收入核算管理不到位，2023年一季报、半年报、三季报存在 收入跨期，相关信息披露不准确。 整改措施：根据《企业会计准则第 28 号——会计政策、会计估计变更和差 错更正》《公开发行证券的公司 ...